LIPO: Lipella Pharmaceuticals Inc. Stock

by  •  • Comments Off on LIPO: Lipella Pharmaceuticals Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.00
Enterprise Value ($M) 0.90
Book Value ($M) 2.56
Book Value / Share 0.34
Price / Book 1.17
NCAV ($M) 2.44
NCAV / Share 0.32
Price / NCAV 1.23

Profitability (mra)
Return on Invested Capital (ROIC) -1.77
Return on Assets (ROA) -1.36
Return on Equity (ROE) -1.52

Liquidity (mrq)
Quick Ratio 5.46
Current Ratio 5.46

Balance Sheet (mrq) ($M)
Current Assets 3.01
Assets 3.14
Liabilities 0.58
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.45
Operating Income -4.75
Net Income -4.62

Cash Flow Statement (mra) ($M)
Cash From Operations -3.15
Cash from Investing -0.01
Cash from Financing 1.34

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
05-06 13D/A Kaufman Jonathan H 19.30 -1.63
03-15 13D/A Chancellor Michael B 20.00 10.36
02-07 13G/A Gruber Michele 5.50 3.30
01-25 13G/A Huang Leaf 9.60 0.00
01-03 13G Sabby Management, Llc 9.99

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023, or ☐ TRANSITION
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023, or ☐ TRANSITION REPO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-07-26 8,817 50,110 17.60
2024-07-25 2,166 85,889 2.52
2024-07-24 16,728 71,348 23.45
2024-07-23 1,600 30,911 5.18
2024-07-22 3,966 32,143 12.34

(click for more detail)

Similar Companies
LEXX – Lexaria Bioscience Corp. LFVN – LifeVantage Corporation
LGVN – Longeveron Inc. LIXT – Lixte Biotechnology Holdings, Inc.
LPCN – Lipocine Inc.


Financial data and stock pages provided by
Fintel.io